Effect of Belimumab on Antibody Titers in Primary APS Patients
Status:
RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the regulatory effect of Belimumab on the antiphospholipid antibody (aPL) as well as to observe related past and new clinical events in primary antiphospholipid syndrome patients.